FDA
[World Report] FDA rejects novel diabetes drug over safety fears
The US Food and Drug Administration has said that it will not approve first-in-class diabetes drug dapaglifozin until more trial data become available. Talha Khan Burki reports.
Rosiglitazone, Myocardial Ischemic Risk, and Recent Regulatory Actions
OBJECTIVE: To review the evidence surrounding rosiglitazone and ischemic cardiovascular risk and discuss the Food and Drug Administration (FDA) decision to revise safety information and restrict access to the drug.
FDA faces barrage of criticism over plans to assess safety of supplements
A plan by the US Food and Drug Administration to assess the safety of nutritional supplements is facing criticism for being not enough to protect the public from harm.
